Dr. Scott Tagawa, MD
Claim this profileWeill Cornell Medical College
Expert in Prostate Cancer
Studies Renal Cell Carcinoma
14 reported clinical trials
32 drugs studied
Area of expertise
1Prostate Cancer
Global LeaderStage IV
2Renal Cell Carcinoma
Stage IV
Stage III
TFE-3/B translocation positive
Affiliated Hospitals
Clinical Trials Scott Tagawa, MD is currently running
ARX517 + Enzalutamide
for Prostate Cancer
This trial is testing ARX517, a new drug, in adults with advanced prostate cancer that doesn't respond to usual treatments. The study aims to see if the drug is safe and effective in stopping or slowing down cancer growth.
Recruiting1 award Phase 17 criteria
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
More about Scott Tagawa, MD
Clinical Trial Related3 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Scott Tagawa, MD has experience with
- 225Ac-J591
- Pembrolizumab
- Abiraterone Acetate
- Apalutamide
- Prednisone
- ARX517
Breakdown of trials Scott Tagawa, MD has run
Prostate Cancer
Renal Cell Carcinoma
Kidney Cancer
Prostate Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott Tagawa, MD specialize in?
Scott Tagawa, MD focuses on Prostate Cancer and Renal Cell Carcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Scott Tagawa, MD currently recruiting for clinical trials?
Yes, Scott Tagawa, MD is currently recruiting for 6 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Scott Tagawa, MD has studied deeply?
Yes, Scott Tagawa, MD has studied treatments such as 225Ac-J591, Pembrolizumab, Abiraterone Acetate.
What is the best way to schedule an appointment with Scott Tagawa, MD?
Apply for one of the trials that Scott Tagawa, MD is conducting.
What is the office address of Scott Tagawa, MD?
The office of Scott Tagawa, MD is located at: Weill Cornell Medical College, New York, New York 10065 United States. This is the address for their practice at the Weill Cornell Medical College.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.